Jump to main content
Jump to site search


Biomaterials-assisted drug delivery for interstitial cystitis/bladder pain syndrome treatment

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic and painful bladder condition afflicting patients with increased urinary urgency and frequency as well as incontinence. Owing to the elusive pathogenesis of IC/BPS, obtaining effective therapeutic outcomes remain challenging. Current administrational routes such as intravesical-bladder injection improves the treatment efficacy and reduces systemic side effects. However, the bladder permeability barrier hinders drug penetration into the bladder wall to meet the desired therapeutic expectation. These issues can be addressed by encapsulating drugs into biomaterials. When appropriately exploited, they would increase drug dwelling time in the bladder, enhance penetration of mucosa and improve the therapeutic response of IC/BPS. In this review, we first elucidate the pathogenesis and animal models of IC/BPS. Then, we highlight recent representative biomaterial-assisted drug delivery systems for IC/BPS treatment. Finally, we discuss the challenges and outlook for further developing biomaterials-based delivery systems for IC/BPS management.

Back to tab navigation

Article information


Submitted
28 Aug 2020
Accepted
09 Oct 2020
First published
14 Oct 2020

J. Mater. Chem. B, 2020, Accepted Manuscript
Article type
Review Article

Biomaterials-assisted drug delivery for interstitial cystitis/bladder pain syndrome treatment

Z. Lin, H. Hu, B. Liu, Y. Chen, Y. Tao, X. Zhou and M. Li, J. Mater. Chem. B, 2020, Accepted Manuscript , DOI: 10.1039/D0TB02094J

Social activity

Search articles by author

Spotlight

Advertisements